A 'mix and match' approach to SARS-CoV-2 vaccination.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34312555.
- Also identified by DOI 10.1038/s41591-021-01463-x and PMC identifier 12036724.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses compared to the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.
Medical subject headings
- COVID-19
- SARS-CoV-2